Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Bavituximab Plus SBRT for Unresectable HCC
NCT02989870Phase 1Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2017
- Primary completion
- Oct 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bavituximab in hepatocellular carcinoma (HCC), sponsored by Moffitt Cancer Center. Primary endpoint: Occurrence of Treatment Related Adverse Events. Planned start Mar 2017; status: withdrawn.
02
Drugs
bavituximab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02989870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989870.